REPORT: Amgen sweetens offer for Onyx, bid falls short of share price
This article was originally published in Scrip
Executive Summary
Amgen increased its bid for Onyx Pharmaceuticals to $130 a share, a move that would value the takeover at about $10.9 billion, Bloomberg News reported.